» Articles » PMID: 28360465

Diagnosis and Management Options in Malignant Pleural Effusions

Overview
Journal Lung India
Specialty Pulmonary Medicine
Date 2017 Apr 1
PMID 28360465
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant pleural effusion (MPE) denotes an advanced malignant disease process. Most of the MPE are metastatic involvement of the pleura from primary malignancy at lung, breast, and other body sites apart from lymphomas. The diagnosis of MPE has been traditionally made on cytological examination of pleural fluid and/or histological examination of pleural biopsy tissue that still remains the initial approach in these cases. There has been tremendous advancement in the diagnosis of MPE now a day with techniques i.e. characteristic Ultrasound and computed tomography features, image guided biopsies, fluorodeoxyglucose-positron emission tomography imaging, thoracoscopy with direct biopsy under vision, tumor marker studies and immunocytochemical analysis etc., that have made possible an early diagnosis of MPE. The management of MPE still remains a challenge to pulmonologist and oncologist. Despite having various modalities with better tolerance such as pleurodesis and indwelling pleural catheters etc., for long-term control, all the management approaches remain palliative to improve the quality of life and reduce symptoms. While choosing an appropriate management intervention, one should consider the clinical status of the patient, life expectancy, overall cost, availability and comparative institutional outcomes, etc.

Citing Articles

Analysis of Cellular DNA Content in Pleural Effusion by Flow Cytometry During Lung Cancer Progression: A Case Report.

Vasilescu M, Panait M, Dumitru M Cureus. 2025; 16(12):e76208.

PMID: 39840198 PMC: 11750209. DOI: 10.7759/cureus.76208.


Rapid Development of Primary Right Atrial Angiosarcoma.

Talbot S, Bandaru V, Nguyen T, Arif D, Sethi P Cureus. 2024; 16(7):e64273.

PMID: 39131000 PMC: 11315593. DOI: 10.7759/cureus.64273.


Comparative Evaluation of Chest Ultrasonography and Computed Tomography as Predictors of Malignant Pleural Effusion: A Prospective Study.

Shehata S, Almalki Y, Basha M, Hendy R, Mahmoud E, Abd Elhamed M Diagnostics (Basel). 2024; 14(10).

PMID: 38786339 PMC: 11120087. DOI: 10.3390/diagnostics14101041.


Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion.

Lee S, Kim K, Lee E, Lee K, Ahn K, Park H NPJ Precis Oncol. 2024; 8(1):111.

PMID: 38773241 PMC: 11109121. DOI: 10.1038/s41698-024-00609-7.


Metastatic papillary thyroid carcinoma in pleural effusion: a case report and review of the literature.

Abutalib M, Shams A, Tamur S, Khalifa E, Alnefaie G, Hawsawi Y J Med Case Rep. 2023; 17(1):521.

PMID: 38115146 PMC: 10731747. DOI: 10.1186/s13256-023-04265-6.


References
1.
Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P . Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004; 125(2):489-93. DOI: 10.1378/chest.125.2.489. View

2.
Davis S, Henschke C, Yankelevitz D, Cahill P, Yi Y . MR imaging of pleural effusions. J Comput Assist Tomogr. 1990; 14(2):192-8. DOI: 10.1097/00004728-199003000-00006. View

3.
Porcel J . Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med. 2013; 34(1):27-37. DOI: 10.1016/j.ccm.2012.11.002. View

4.
Lee Y, Light R, Musk A . Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med. 2000; 6(4):267-74. DOI: 10.1097/00063198-200007000-00003. View

5.
Botana Rial M, Lamela I, Leiro Fernandez V, Abal Arca J, Delgado M, Pombo C . Management of malignant pleural effusion by an indwelling pleural catheter: A cost-efficiency analysis. Ann Thorac Med. 2015; 10(3):181-4. PMC: 4518348. DOI: 10.4103/1817-1737.160837. View